News

Operating loss was $8.8m, compared to $7.09m for the comparable period in 2009. For the nine months ended 30 September 2010, Chelsea has posted a net loss of

As per the terms of the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca

Depomed has posted a net income of $1.89m for the third quarter 2010, or $0.04 per diluted share, compared to $1.37m, or $0.03 per diluted share, for the

Heading up the center will be Bei Betty Zhang, a native of Shanghai and a diabetes expert who also serves as vice president of Research for Lilly Research

Pfizer posted a net income of $866m for the third quarter 2010, or $0.11 loss per diluted share, a decrease of 70%, compared to $2.88bn, or $0.43 loss

Teva posted a net income of $1.05bn for the third quarter 2010, or $1.15 per diluted share, compared to $649m, or $0.72 per diluted share, for the comparable

Reviewed by scientists at the Department of Health and Human Services, the research grant has been awarded to X-BODY for its human monoclonal antibody therapeutic project targeting metastatic

Depomed is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and

The acquisition will allow Nycomed to gain access to a number of biologic and protein-based drugs manudactured by Techpool. Techpool has developed and launched a number of protein